We are pleased to announce that the TALGiTS trial has now closed to recruitment, having successfully reached our target of 250 participants.

We would like to offer our sincere thanks to all the participants, research teams, and sites whose efforts made this possible.

Details of the trial.

Trial of Alginates in Throat Symptoms 

The TALGiTS study looked at the use of Gaviscon Advance in comparison to placebo (a ‘dummy’ treatment) for the treatment of persistent throat symptoms during an 8-week treatment period prior to participants first outpatient clinic appointment.

Approximately 250 people took part in this study which was conducted at 15 sites across the UK.

Who could participate?

If participants had been referred to ENT or SaLT clinic with persistent throat symptoms (hoarse voice, lump in throat sensation, throat clearing, cough, post-nasal secretions / catarrh, throat discomfort) and were aged 18 or over they were eligible to take part in the TALGiTS trial.  

What did taking part involve?

The intention was to run this trial with as much remote participant contact as possible using telephone, video consultations or any other suitable methods of contact. There was one in person clinic visit planned at the end of the trial, which would be the standard clinic appointment participants would have received following their referral.  Participants were involved in the trial for 8-weeks.

The information on this website is for Trial Participants.